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Abstract
Background: Burning mouth disorder (BMD) is a burning or stinging sensation affecting the oral mucosa, lips, and/
or tongue, in the absence of clinically visible mucosal lesions. There is a strong female predilection, with the age of 
onset being approximately 50 years. 
The causes of BMD are multifactorial and remain poorly understood. 
Often BMD patients report, in association, change in taste.
In this regards, it is relevant that in central nervous system connections exist between taste and oral pain and that 
taste normally inhibits oral pain. 
Aim: The working hypothesis of this study considers a possible relationship between burning mouth disorders and 
alterations of taste. Several conditions or pathologies can be responsible of taste disturbances that might be the cause 
of oral pain in BMD patients.
Subjects and methods: We have analyzed, retrospectively, 142 cases of BMD with associated taste disturbance. Pos-
sible causes that could be responsible for alterations of taste were investigated.
Results and conclusions: Sixty-one subjects revealed the habitual use of drugs having a documented interference with 
taste perception. Thirty-five subjects, among  the 81 patients who had no associated pathology or  habitual use of 
drugs, noticed in their clinical history conditions, pathologies or use of drugs that are known to affect the gustatory 
system. Therefore, we propose that   BMD may represent an oral phantom pain induced in susceptible individuals 
by alteration of taste.
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Introduction
Burning mouth disorder (BMD) is a chronic, intraoral 
burning sensation occurring in the absence of identifiable 
oral lesions or laboratory abnormalities (1).  The most 
common intraoral site involved is the anterior tongue, 
but other sites can be affected including the hard palate, 
lips and less frequently the cheek.  The patients usually 
describe the sensation as a burning, tingling, or numbness 
of some part of the oral cavity, and often describe it as 
a feeling that the mouth has been burnt by hot tea or 
coffee (2). 
A multitude of studies have demonstrated psychological 
changes in BMD subjects including anxiety and depres-
sion. The presence of such psychological symptoms in 
combination with the absence of  clinical findings has 
caused BMD to be viewed as a primarily psychological 
disorder, a belief  fueled by the lack of responsiveness of 
BMD to different treatments (3-7).
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In contrast to the above, there is a growing body of eviden-
ce that BMD may not always be psychological at origin, 
and may prove to be a model for other pain disorders both 
in the orofacial area and elsewhere (8-12). Burning and 
pain, the main features in BMD, are also characteristic 
features of  some post-traumatic nerve injuries.  In the 
latter, however, additional sensory abnormalities are often 
present which manifest as changes in perception of touch, 
temperature, two-point discrimination and pain (13, 14). 
No definite neurological causes of BMD have yet been 
identified but we have provided some evidence that it may 
be an intraoral form of neuropathic pain (15).
Patients with oral burning often report taste illness with 
dysgeusie or hypogeusie.
Thus, we have hypothesized that BMD may associated 
with or depend on taste disorders.
 
Subjects and Procedures
Obiectives 
Aim of this study is to evaluate a possible relationship 
between BMD and taste disorders.
Inclusion criteria
We have analyzed 142 Italian patients affected by BMD 
(85 females and 57 males; median age 53 years).
All patients came to our clinical observation in a period 
referred to 2004-2005 complaining of oral burning associa-
ted to taste disorders (disgeusie or hypogeusie or normal 
taste but no flavor) in absence of any oral pathological 
evidence which could justify the oral pain. In particular, 
the majority of patients reported a reduction of bitter taste 
(hypogeusia) and metallic taste (dysgeusia).
BMD diagnosis was performed after using of a blood and 
instrumental protocol as listed in Table 1 and excluding 
whatever haematic and instrumental alteration.
Exclusion criteria
Patients having history of contact allergy and parafunctio-
nal habit were excluded from our study.  Patients with 
associated pathologies that could be responsible for oral 
burning were excluded: oral candidiasis, gastroesophageal 
reflux disease, diabetes, anemia,  Sjögren's syndrome, nu-
tritional deficiencies ( vitamin B-12, niacin, iron, or folic 
acid), and HIV.
Every patient was informed of the purpose of our study 
and informed consent was obtained.
Study design
Medical history of every patient  was considered. Parti-
cular attention was paid on the presence of concomitant 
pathologies and/or use of drugs.
Data were analyzed by Wilcoxon signed rank test.
Results
The results obtained by clinical and anamnestic exami-
nation of the 142 BMD patients with taste disorder and 
the list of drugs taken are shown in Table 2. Sixty-one 
patients revealed concomitant pathologies along with use 
of various drugs (BMD-A). The list of substances that 
are documented to interfere with taste is shown in Table 
3 (16-22); On the basis of such data which are reported 
from the data bank of drug –vigilance ”Banque Nationale 
Française de Pharmacovigilance”, it appeared that most 
drugs taken by BMD patients have been shown to cause 
taste disturbance (23).
In the majority of  these cases, whenever possible, the 
substitution of the indicted drug   allowed a spontaneous 
resolution of taste disturbance and a contemporary re-
duction or resolution of oral burning.
For the 81 patients (BMD-B), who had reported no asso-
ciated pathologies or habitual use of drugs, the  diagnosis 
of BMS (burning mouth syndrome) was performed. The 
clinical history of  these subjects, retrospectively, was 
considered.  
Therefore we analysed conditions, minor pathologies or 
occasional use of drugs happened 30 -60 days before the 
onset of oral burning along with taste disorder. For 46 
patients, we didn't discover any pathological conditions 
that were supposed to be able to trigger oral burning or 
taste change. For 14 patients, herpes simplex, herpes zoster, 
mastoiditis and purulent otitis media were detected. Five 
patients revealed a transitory hypoaesthesia to the lower 
lip, the anterior hard palate or one side of the tongue 
after influenzal episodes or a local anaesthesia for dental 
treatment in the lower dental arch before the onset of 
BMD. Head trauma was found in recent medical history 
for two subjects. All the above conditions or pathologies 
have been demonstrated to be responsible for damage of 
nervous tract of taste. Other 14 subjects reported previous 
use of antibiotics which are known to interfere with taste 
receptors (Table 4).  For these subjects, there was spon-
taneous complete or partial resolution of oral subjective 
symptomatology following the resolution of transitory 
pathology or condition in about 1-3 months and in absence 
of drugs therapy (24-28).
Full blood count
Random blood glucose
Alanine and aspartate transaminase
Serum ferritin
Serum total  IgE ( paper radio-immunoadsorbent 
test = PRIST)
Serum vitamin Vit. B12
Serum antinuclear (ANA) and extractable nuclear 
antibodies (ENA)
Serum antibodies to Helicobacter Pylori
Scintigraphy glands salivar
Oral tampon for candida research
Table 1. Blood and instrumental protocol for BMD diag-
nosis.
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Concomitant pathologies
Number of patients affected
X (n females)
(%) of patients affected Drugs taken
Several kind of  
pathologies in single 
form or associated 
(BMD-A)
61 (32 F) 43
None (BMD-B) 81 (53 F) 57
For 61 patients (BMD-A)
Kind of pathologies Total number for pathology
Hypothyroidism 17* (11 F) Thyroxine
Depression 14* (9 F)
Zopiclone, Benzodiazepine, 
Carbamezapine
Hyperthyroidism 3* (2  F) Carbimazole, propyluracil
Hypertension 13* (6 F) ACE-inhibitor
Hypercholesterolemia 16* (10 F) Statin
Colitis 2* (1 F) Sulphasalazine
Ischaemic heart disease 11* (5 F)
Calcium-antagonist, beta-
blockers, nitrates, heparin
Obstructive pulmonary 
disease
5*  (2 F) Beta2-agonist
Cardiovascular
ACE inibitors
Calcium antagonists
Beta blockers
Antimicrobials
Terbinafine
Imidazole
Mefloquine
Macrolides
Quinolines
Antiinflammatory
D-penicillamine
Hydroxychloroquine
Sodium aurothiomalate
NSAIDs
Aspirin
Cortisone
Central nervous system
Zopiclone
Zolpidem
Carbamazepine
Endocrine and metabolic
Carbimazole
Propylthiouracil
Statin
Fibrate
Antineoplastic
Methotrexate
Cyclophosphamide
Epirubicin
Ciclosporin
Gastrointestinal
Sulphasalazine
Domperidone
Beta2-agonists
Number % Pathology or drug use
46* 57 None detectable
5* 6 Oral hypoaesthesia
3 * 4 Oral herpes simplex
4 * 5 Facial herpes zoster
4* 5 Purulent otitis media
3* 4 Mastoiditis
2* 2 Head trauma
14* 17 Antibiotics 
Imidazole
Macrolides
Quinolones
Peniciline
* Wilcoxon signed rank test P value is 0,0039
Table 2. Concomitant pathologies and drugs used  in BMD patients.
Table 3. Drugs interfering with taste (15-21).
*Wilcoxon signed rank test P value is 0,0156
Table 4. Pathologies and condition or drug use found in pre-
vious clinical history for  81 BMD-B patients with no current 
medical history.
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Discussion and Conclusion
In this retrospective study, we have attempted to evaluate 
whether changes in taste perception might be responsible 
for some BMD cases. We have found that 61 BMD patients 
revealed associated pathologies for which they took drugs 
known to interfere with taste (BMD-A), as it is quoted in 
the literature (16-22). Furthermore, 35 out of 81 patients 
with BMD without associated systemic diseases (conside-
red as BMS patients: BMD-B) reported in their clinical 
history some pathologies, conditions or use of drugs that 
are recognized to potentially interfere with taste. For all 
these patients (61 BMD-A + 35 BMD-B) we propose that 
taste disturbance may be responsible for oral burning 
and pain, especially in supertaster (persons with higher 
number of papillae). 
Anatomical associations between perception of  taste 
and oral pain support the idea that damage to gustatory 
system might be associated with oral burning phantoms 
as well as taste phantoms (perception of taste in absence 
of stimuli) (29). Thus, BMD could represent an oral pain 
phantom induced, in predisposed individuals, by damage 
to gustatory system.  Normally, taste input inhibits the 
area of  the brain receiving input from the trigeminal 
nerve (30).  Damage to the chorda tympani or disorder 
to the gustatory system release that inhibition leading to 
intensification of normal trigeminal sensations as well as 
phantom trigeminal sensations (31).  Trigeminal sensations 
include oral pain as well as sensations of touch (swelling) 
and oral dryness.
The taste buds are largely diffused in the epithelium of 
dorsal surface of tongue, whereas less represented they 
are within mucosa of the palate, pharynx,  epiglottis and 
third superior of esophagus. In the tongue, the taste buds 
are located in papillae circumvallate, foliate and more in 
fungiform papillae (32, 33). The number of fungiform 
papillae is related to genetic variation in the ability to 
taste, a variation discovered in 1931 when Fox found 
that some individuals could taste the bitter compound 
phenylthiocarbamide (PTC) while others could not (34). 
Subsequent study has shown that individuals unable to 
taste PTC and related chemicals have the smallest number 
of fungiform papillae (35).
Individuals who can taste PTC can be divided into me-
dium and supertasters.  The supertasters have the largest 
number of fungiform papillae.  It may be that women are 
like men supertasters and this would explain explain the 
greater prevalene of BMD in woman than in men.  Each 
fungiform papillae contains, on average, six taste buds and 
each taste bud is surrounded by a basket-like collection 
of pain neurons.  Thus, a supertaster appears to be a su-
perperceiver of oral pain (36, 37). There are several lines 
of evidence supporting this hypothesis that could explain 
why the BMD is found predominantly in postmenopausal 
women. Indeed, the ability to taste bitter substances is 
reduced following menopause due to decrease in estro-
genic rate (38). Furthermore, there is evidence that taste 
normally inhibits oral pain. This was demonstrated by 
anaesthetizing the chorda tympani just on one side. In this 
study the intensity of oral pain produced by capsaicin (the 
compound that makes chilis burn) intensified on the side 
of the tongue contralateral to the anaesthesia; however, 
this occurred in supertasters, not in nontaster ones (6, 
38-40).  Similarly, the reduction of taste perception for 
disturbance to gustatory system, by releasing the inhi-
bition on oral pain, may cause increase in the perceived 
intensity of oral burning  and this is proportional to the 
density of fungiform papillae (supertaster subjects). Con-
sistently, topical anaesthesia of the mouth intensifies oral 
burning sensation in many BMD patients.  Just as with the 
anaesthetic effects on taste phantoms, the intensification 
of a phantom with anaesthesia suggests that the phantom 
arises from release of inhibition (38-42).  
The several drugs utilized  by 61 patients of the BMD-A 
group,  previous conditions and pathologies for 21 subjects 
and previous use of antibiotics for 14 subjects (among 81 
BMD-B patients) might  be responsible for taste disorder 
for chemical interference on development and maturity of 
taste receptors, with subsequent onset of oral pain. This 
suggests that BMS is a sensory phantom that can arise 
when tonic inhibition processes in the central nervous 
system are disrupted (42). 
Damage of the gustatory system, therefore, by releasing 
pain inhibition by taste, might cause to patients to expe-
rience of oral pain in absence of visible oral lesions (43). 
Furthermore, we have recently reported that patients 
with hypothyroidism often suffer from oral burning and/
or dysgeusia. This finding is worth of note given the well 
known effect of thyroid hormones in the maturation of 
fungiform papillae. Thus, hypothyroidism could act as 
a negative factor for the development of papillae, with 
subsequent reduction in taste perception and eventual 
release of inhibition on the trigeminal somatic-sensorial 
sensitivity (44). Pathology such as head trauma and upper 
respiratory infections, otitis media, and herpetic infections 
are known to damage taste and to reduce the perceived 
bitterness of PROP (6-n-propylthiouracil (28,45,46). 
We propose for BMD patients to valuate every condition 
and use of  drugs that could interfere with gustatory 
system and be responsible for BMD. For these cases, 
sometimes, the substitution of this drugs could resolve 
the oral burning. 
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